Third, in lieu of any comprehensive database that tracks outcomes of CDH1 mutation carriers, we calculate an estimated secondary cancer risk among patients with sporadic gastric SRCCs, using the Surveillance, Epidemiology, and End Results (SEER) database. This evidence concerns the gene CDH1 and cancer.